Treatment costs of psoriasis in a tertiary-level clinic

BMC Health Services Research

Risto Tuominen¹  Leena Koulu³  Kalle Mattila³  Mauri Leino³  Anssi Mustonen² 

[1] Department of Public Health, University of Turku and Primary Health Care Unit, Hospital District of Southwest Finland, Turku, Finland;University of Turku, Lemminkäisenkatu 1, 20014 Turku, Finland;Department of Dermatology, Turku University Hospital and University of Turku, Turku, Finland

关键词: Phototherapy;    Cost;    Psoriatic arthritis;    Psoriasis;   

Others  :  1126765
DOI  :  10.1186/1472-6963-14-344

 received in 2014-05-15, accepted in 2014-08-13,  发布年份 2014

【 摘 要 】

Background

The costs of psoriasis to a tertiary-level clinic vary considerably depending on the country of study and methods used. Hospitalisation and phototherapy have been significant cost components. This study was performed to estimate the distribution and relative magnitude of the costs of psoriasis to a tertiary-level clinic.

Methods

Based on 233 patients, outpatient and phototherapy visits and the days hospitalised were collected from the treatment provider’s records. The visit costs represented true costs, used to charge the final payers. Patients were analysed according to their treatment modalities.

Results

On average, hospitalised patients (3.4%) had 31-fold higher total costs than non-hospitalised patients (p < 0.0001). The costs of hospitalisations formed 45% of all the treatment costs to the entire study population. Phototherapy accumulated 19% of the overall treatment costs. Patients receiving biological drugs or both phototherapy and traditional systemic therapy had the highest costs of treatment.

Conclusions

The current study indicates that a small percentage of all psoriasis patients generate a large proportion of the overall costs to a tertiary-level hospital. Treatment modality has a significant effect on the costs to a tertiary-level hospital.

【 授权许可】

   
2014 Mustonen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Raychaudhuri SP, Farber EM: The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001, 15(1):16-17.
• [2]Radtke MA, Augustin M: Economic considerations in psoriasis management. Clin Dermatol 2008, 26(5):424-431.
• [3]Kaipiainen-Seppanen O: Incidence of psoriatic arthritis in Finland. Br J Rheumatol 1996, 35(12):1289-1291.
• [4]Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53(4):573.
• [5]Raho G, Koleva DM, Garattini L, Naldi L: The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics 2012, 30(11):1005-1013.
• [6]Levy AR, Davie AM, Brazier NC, Jivrai F, Albrecht LE, Gratton D, Lynde CW: Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 2012, 51(12):1432-1440.
• [7]Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, Clark AR: The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997, 37(4):564-569.
• [8]Navarini AA, Laffitte E, Conrad C, Piffaretti P, Brock E, Ruckdaeschel S, Trueb RM: Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010, 140(5–6):85-91.
• [9]Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR: The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat 2006, 17(1):29-37.
• [10]Feldman SR, Evans C, Russell MW: Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat 2005, 16(1):37-42.
• [11]Steinke SI, Peitsch WK, Ludwig A, Goebeler M: Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS One 2013, 8(10):e78152.
• [12]Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Storm BL: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007, 143(12):1493-1499.
• [13]Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallet DA, Kosicki G: The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008, 59(5):772-780.
• [14]Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41(3 Pt 1):401-407.
• [15]Carrascosa JM, Pujol R, Dauden E, Hernanz-Hermiosa JM, Bordas X, Smandia JA, Ferrandiz C: A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006, 20(7):840-845.
• [16]Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, Costanzo A, Di Cesare A, Lapucci E, Chimenti S: Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008, 4(2):559-568.
• [17]Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A: Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol 2012, 22(2):238-245.
• [18]Berger K, Ehlken B, Kugland B, Augustin M: Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005, 3(7):511-518.
• [19]Sohn S, Schoeffski O, Prinz J, Rauner K, Schubert E, Sohn S, Reich K: Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006, 212(2):137-144.
• [20]Tang MM, Chang CC, Chan LC, Heng A: Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. Int J Dermatol 2013, 52(3):314-322.
• [21]Cockayne SE, Cork MJ, Gawkrodger DJ: Treatment of psoriasis: day care vs. inpatient therapy. Br J Dermatol 1999, 140(2):375-376.
• [22]Javitz HS, Ward MM, Farber E, Nail L, Vallow SG: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46(6):850-860.
• [23]Stern RS: PUVA Follow-up Study. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J Am Acad Dermatol 2003, 49(3):445-450.
• [24]Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R: Influence of psoriasis on work. Eur J Dermatol 2013, 23(2):208-211.
• [25]Finzi AF, Mantovani LG, Belisari A, Italian Association for Studies on Psoriasis: The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol 2001, 15(4):320-324.
• [26]Vensel E, Hilley T, Trent J, Taylor JR, Kilsner RS, Kerdel FA, Taylor JR, Scwartzberg JB: Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol 2000, 43(5 Pt 1):858-860.
• [27]Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R: The costs of psoriasis medications. Dermatol Ther (Heidelb) 2013, 3(2):169-177.
• [28]Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM: The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010, 162(6):1324-1329.